# Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

Study · id `cardio:ct-nct04634916` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04634916](<https://clinicaltrials.gov/study/NCT04634916>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04634916

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

## Technical summary

Registry record NCT04634916. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-26 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 220 participants (planned count; ClinicalTrials.gov record NCT04634916, source copy `cardio:ctgov-nct04634916-2026-08-10`, retrieved 2026-10-26)
- Started: 2021-03-26 (actual) (ClinicalTrials.gov record NCT04634916, source copy `cardio:ctgov-nct04634916-2026-08-10`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT04634916, source copy `cardio:ctgov-nct04634916-2026-08-10`, retrieved 2026-10-26)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT04634916, source copy `cardio:ctgov-nct04634916-2026-08-10`, retrieved 2026-10-26)
- Countries: United States; Australia (ClinicalTrials.gov record NCT04634916, source copy `cardio:ctgov-nct04634916-2026-08-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04634916-2026-08-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- Acronym: CONNECT-AV
- Condition: Kidney Disease, End-Stage
- Condition: End-stage Renal Disease
- Condition: Arteriovenous Fistula
- Intervention (Device): EndoAVF Creation
- Lead sponsor: C. R. Bard
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: C. R. Bard (`cardio:org-c-r-bard`)

## Provenance

Content hash: 757755114f2467c0919de83a220ae1b0e6e3721b191478aa145ccebc1d2621a3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
